In agreement with our findings, bortezomib-evoked apoptosis correlates with the induction of DDIT3 expression in osteosarcoma cells [57] and DDIT3 silencing inhibits death of non-small cell lung cancer and multiple myeloma cells co-treated with nelfinavir and bortezomib [58]. Here, DDIT3 is linked to plasma cell myeloma.